

UCLA

UCLA Previously Published Works

Title

Diagnostic challenges from conflicting results of tests and imaging

Permalink

<https://escholarship.org/uc/item/3mf020v3>

Journal

World Journal of Clinical Cases, 12(24)

ISSN

2307-8960

Author

Yu, Run

Publication Date

2024-08-26

DOI

10.12998/wjcc.v12.i24.5448

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <https://creativecommons.org/licenses/by-nc/4.0/>

Peer reviewed



Diagnostic challenges from conflicting results of tests and imaging

Run Yu

Specialty type: Medicine, research and experimental

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade C

Novelty: Grade B

Creativity or Innovation: Grade C

Scientific Significance: Grade C

P-Reviewer: Ozaki T

Received: February 25, 2024

Revised: May 13, 2024

Accepted: May 20, 2024

Published online: August 26, 2024

Processing time: 136 Days and 17.4 Hours



Run Yu, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, United States

Corresponding author: Run Yu, MD, PhD, Professor, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 200 Medical Plaza Driveway #530, Los Angeles, CA 90095, United States. runyu@mednet.ucla.edu

Abstract

Accurate diagnosis is the foundation of clinical care but accurate diagnosis is not easily reached in some cases. In rare instances, even a sophisticated multidisciplinary team at an academic medical center cannot reliably reach an accurate diagnosis after extensive testing and imaging, and has to wait until histological diagnosis or even autopsy results are available. The underlying reason of challenging diagnoses is mostly conflicting data from history, tests, and imaging that point to different diagnoses. In this issue of *World Journal of Clinical Cases*, Huffaker *et al* reported such a challenging case of a tricuspid mass in a patient with Li-Fraumeni syndrome. The case by Huffaker *et al* powerfully illustrates the occasional diagnostic challenges inherent in our current diagnostic approach and the current technology. Clinicians should realize that in rare situations, agnosticism in diagnosis is unavoidable but a treatment has to be initiated so long as the principle of *primum non nocere* is upheld.

Key Words: Li-Fraumeni syndrome; Cardiac mass; Thrombus; Challenging diagnosis; Histological diagnosis; False positive results

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The underlying reason of challenging diagnoses is mostly conflicting data from history, tests, and imaging that point to different diagnoses. The case by Huffaker *et al* powerfully illustrates the occasional diagnostic challenges inherent in our current diagnostic approach and technology. Clinicians should realize that in rare situations, agnosticism in diagnosis is unavoidable but a treatment has to be initiated so long as the principle of *primum non nocere* is upheld.

Citation: Yu R. Diagnostic challenges from conflicting results of tests and imaging. *World J Clin Cases* 2024; 12(24): 5448-5451

URL: <https://www.wjgnet.com/2307-8960/full/v12/i24/5448.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v12.i24.5448>

INTRODUCTION

Accurate diagnosis is the foundation of clinical care but accurate diagnosis is not easily reached in some cases. In rare instances, even a sophisticated multidisciplinary team at an academic medical center cannot reliably reach an accurate diagnosis after extensive testing and imaging, and has to wait until histological diagnosis or even autopsy results are available. The underlying reasons of challenging diagnoses fall into two categories: Much more commonly, conflicting data from history, tests, and imaging that point to different diagnoses, and less commonly, failure to recognize a potential novel disease[1].

CONFLICTING DIAGNOSTIC RESULTS

Conflicting results from tests and imaging are quite common in clinical practice; most experienced clinicians are well versed in teasing out common conflicting results from tests and imaging. For example, normal hemoglobin A1c in a patient with history of poorly controlled diabetes and severe hyperglycemia who has just received blood transfusion is well recognized as a false negative result due to transfusion. As the disease becomes rarer, specialists need to be called upon to interpret conflicting results. For example, pancreastatin and chromogranin A, both markers of neuroendocrine tumor, may be much elevated and normal, respectively, but elevated pancreastatin can be false positive due to spurious test method[2]. Our experience with imaging follows the same pattern. It is well known that renal cell carcinoma can have normal fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) so that a normal FDG uptake cannot rule out the cancer. When dodecane tetraacetic acid octreotate (DOTATATE)-PET first became available, uptake at the pancreatic head/neck region without computed tomography (CT) correlates often was thought as evidence of pancreatic neuroendocrine tumor. Accumulating experience and research over the years now show that the DOTATATE uptake at the pancreatic head/neck region is most often due to pancreatic polypeptide cell pseudohyperplasia[3]. Thus at academic centers, multidisciplinary teams of experts from various specialties usually can reach a correct diagnosis based on history, laboratory tests, and imaging, before histological evidence is required. Once in a while, even a team of experts cannot reliably make an accurate diagnosis.

AN ILLUSTRATIVE CASE

In this issue of World Journal of Clinical Cases, Huffaker *et al*[4] reported such a challenging case of a tricuspid mass in a patient with Li-Fraumeni syndrome (LFS). LFS is an autosomal dominant disease of multiple malignancies due to inactivating mutations of tumor suppressor P53. Common malignancies in LFS include soft tissue sarcoma, osteosarcoma, and breast cancer. The 30-year-old female described by Huffaker *et al*[4] had clearly diagnosed LFS with history of multiple LFS-defining malignancies. She also had two atrial septal defects so underwent periodic echocardiogram for signs of right heart enlargement. The latest transthoracic echocardiogram showed a 1-cm mass on the tricuspid valve, which had not been present a year before. Clinically she was well and exhibited no cardiac signs or symptoms.

The differential diagnosis of a cardiac mass includes tumor, thrombus, and vegetation[5]. To pinpoint the diagnosis without histology is often challenging. Clinical history and imaging characteristics of the mass are helpful predictors of a diagnosis. For example, a left ventricular mass in a patient with embolic stroke and reduced left ventricular wall motion is most likely a thrombus[6]. In this young female with LFS, tumor was a concern as cardiac sarcoma has been reported in LFS[7]. The patient was also at high risk of thrombus due to hypercoagulability associated with extensive malignancy history. The case report did not specify whether the patient was taking oral contraceptives or other hormonal therapies, which has been associated with tricuspid thrombus presumably due to hormonally-related hypercoagulability[8]. As she overall felt well and presumably did not have fever or anemia, vegetation was highly unlikely and could be ruled out clinically. There are no laboratory tests to differentiate a cardiac tumor from a thrombus; detailed imaging is needed to further characterize the tricuspid mass. Transesophageal echocardiogram describes the location, shape, and motion of a cardiac mass in real time but does not particularly tell the nature of the mass. In this case, transesophageal echocardiogram showed that the mass was attached to the anterior tricuspid valve leaflet, presumably without abnormal blood flow through the right heart. Magnetic resonance imaging (MRI) is the most commonly used imaging modality to differentiate a cardiac tumor from a thrombus with the late gadolinium enhancement protocol based on the reasonable assumption that a thrombus should not have significant blood supply[9]. In this case, gadolinium enhancement was noted on the tricuspid mass, which was interpreted as imaging evidence of tumor. Could the authors use additional imaging? FDG-PET/CT has been used to differentiate a cardiac tumor from a thrombus but it has also been subject to falsely suggesting malignancy in a case of organized thrombus[10].

In a challenging case like this one, the next critical question is whether making an accurate diagnosis (*i.e.*, a tricuspid tumor *vs* thrombus) affects management? A tricuspid tumor would require surgical resection but a tricuspid thrombus could potentially be treated with anticoagulation. Anticoagulation, however, is associated with risk of embolism, and in this case, pulmonary embolism, which is a serious adverse effect[11]. The authors opted to stop at the MRI and proceeded with surgical resection, regardless whether this was a tricuspid tumor or thrombus. The histology showed that the tricuspid mass was actually an organized thrombus.

CONCLUSION

The case by Huffaker *et al*[4] powerfully illustrates the occasional diagnostic challenges inherent in our current diagnostic approach and the current technology. Clinicians should realize that in rare situations, agnosticism in diagnosis is unavoidable and an accurate diagnosis simply cannot be made, but a treatment has to be initiated so long as the principle of *primum non nocere* is upheld. Technological advances such as radiomics and artificial intelligence may aid us achieving a more accurate diagnosis[12,13].

FOOTNOTES

Author contributions: Yu R wrote the paper.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: United States

ORCID number: Run Yu 0000-0003-2901-5102.

S-Editor: Gao CC

L-Editor: A

P-Editor: Xu ZH

REFERENCES

- 1 Yu R. Interpretation of Unexpectedly High Levels of Endocrine Tumor Markers. *Endocr Pract* 2018; **24**: 841-847 [PMID: 30106635 DOI: 10.4158/EP-2018-0166]
- 2 Sagum J, Yu R. False-Positive Pancreastatin Results From a Commercial Laboratory: A Report of 2 Cases. *Pancreas* 2021; **50**: e33-e35 [PMID: 33835984 DOI: 10.1097/MPA.0000000000001774]
- 3 Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, Pettinato V, Malizia C, Lodi F, Fanti S. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. *J Nucl Med* 2011; **52**: 886-890 [PMID: 21571796 DOI: 10.2967/jnumed.111.088328]
- 4 Huffaker T, Pak S, Asif A, Otchere P. Tricuspid mass-curious case of Li-Fraumeni syndrome: A case report. *World J Clin Cases* 2024; **12**: 1936-1939 [PMID: 38660548 DOI: 10.12998/wjcc.v12.i11.1936]
- 5 Scally B, Pl C, Anghinah R, Ma P. Event-Related Potentials in the Continuum of Alzheimers Disease: Would they Suit recent Guidelines for Preclinical Assessment? *J Clin Diagn Res* 2016; **04** [DOI: 10.4172/2376-0311.1000127]
- 6 Buchbinder NA, Yu R, Rosenbloom BE, Sherman CT, Silberman AW. Left ventricular thrombus and embolic stroke caused by a functional paraganglioma. *J Clin Hypertens (Greenwich)* 2009; **11**: 734-737 [PMID: 20021531 DOI: 10.1111/j.1751-7176.2009.00182.x]
- 7 Insuasty-enríquez JS, Ortega Apraez V, Arias-quiroz EJ, Alarcón-tarazona ML, Calderón-cortés CA. Síndrome de Li-Fraumeni. *Acta Med Col* 2021; **47** [DOI: 10.36104/amc.2022.2198]
- 8 Saxena P, Mejia R, Tam RK. A rare presentation of tricuspid valve thrombus in a normal heart. *Ann Thorac Surg* 2005; **80**: 1498-1500 [PMID: 16181900 DOI: 10.1016/j.athoracsur.2004.04.018]
- 9 Chan AT, Plodkowski AJ, Pun SC, Lakhman Y, Halpenny DF, Kim J, Goldberg SR, Matasar MJ, Moskowitz CS, Gupta D, Steingart R, Weinsaft JW. Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer. *J Cardiovasc Magn Reson* 2017; **19**: 76 [PMID: 29025425 DOI: 10.1186/s12968-017-0390-2]
- 10 Chaudhuri KG, Revels JW, Yadwadkar KS, Johnson LS. Intense 18F-FDG uptake in an organizing right atrial thrombus mimicking malignancy. *Radiol Case Rep* 2017; **12**: 449-454 [PMID: 28828100 DOI: 10.1016/j.radcr.2017.04.023]
- 11 Sakellariou XM, Efsthathopoulos A, Stamatis KV, Nikas DN, Kolettis TM. Treatment of Mobile Right Heart Thrombi. *Eur J Case Rep Intern Med* 2020; **7**: 001918 [PMID: 33313001 DOI: 10.12890/2020_001918]
- 12 Son J, Hong YJ, Kim S, Han K, Lee HJ, Hur J, Kim YJ, Choi BW. Radiomics Feature Analysis Using Native T1 Mapping for Discriminating

- Between Cardiac Tumors and Thrombi. *Acad Radiol* 2022; **29** Suppl 4: S1-S8 [PMID: 33419643 DOI: 10.1016/j.acra.2020.12.009]
- 13 **Madan N**, Lucas J, Akhter N, Collier P, Cheng F, Guha A, Zhang L, Sharma A, Hamid A, Ndiokho I, Wen E, Garster NC, Scherrer-Crosbie M, Brown SA. Artificial intelligence and imaging: Opportunities in cardio-oncology. *Am Heart J Plus* 2022; **15** [PMID: 35693323 DOI: 10.1016/j.ahjo.2022.100126]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

